Asset Details
Do you wish to reserve the book?
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
Do you wish to request the book?
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment
2024
Overview
Glioblastoma multiforme (GBM) acquires resistance to bevacizumab (Bev) treatment. Bev affects angiogenic factors other than vascular endothelial growth factor (VEGF), which are poorly understood. We investigated changes in angiogenic factors under and after Bev therapy, including angiopoietin-1 (ANGPT1), angiopoietin-2 (ANGPT2), placental growth factor (PLGF), fibroblast growth factor 2, and ephrin A2 (EphA2). Fifty-four GBM tissues, including 28 specimens from 14 cases as paired specimens from the same patient obtained in three settings: initial tumor resection (naïve Bev), tumors resected following Bev therapy (effective Bev), and recurrent tumors after Bev therapy (refractory Bev). Immunohistochemistry assessed their expressions in tumor vessels and its correlation with recurrent MRI patterns. PLGF expression was higher in the effective Bev group than in the naïve Bev group (
p
= 0.024) and remained high in the refractory Bev group. ANGPT2 and EphA2 expressions were higher in the refractory Bev group than in the naïve Bev group (
p
= 0.047 and 0.028, respectively). PLGF expression was higher in the refractory Bev group compared with the naïve Bev group for paired specimens (
p
= 0.036). PLGF was more abundant in T2 diffuse/circumscribe patterns (
p
= 0.046). This is the first study to evaluate angiogenic factors other than VEGF during effective and refractory Bev therapy in patient-derived specimens.
Publisher
Springer Science and Business Media LLC,Springer Nature Singapore,Springer Nature B.V
Subject
/ Aged
/ Angiogenesis Inhibitors - therapeutic use
/ Antineoplastic Agents, Immunological - therapeutic use
/ Bevacizumab - therapeutic use
/ Brain Neoplasms - drug therapy
/ Female
/ Glioma
/ Humans
/ Male
/ Medicine
/ Neovascularization, Pathologic - drug therapy
/ Oncology
/ Original
/ Patients
/ Placenta Growth Factor - metabolism
/ Surgery
/ Tumors
